Studies suggest that 50% or more of patients with Lyme disease may carry at least one co-infection. These additional pathogens—Babesia, Bartonella, Ehrlichia, Anaplasma, and Mycoplasma among them—can cause their own symptoms, amplify Lyme symptoms, suppress immune function, and complicate treatment. Treating Borrelia alone without addressing co-infections is one of the most common reasons patients fail to recover.
Why co-infections complicate Lyme treatment
Ixodes ticks—the ticks that transmit Lyme disease—are not single-pathogen carriers. A single tick bite can introduce multiple infectious organisms simultaneously. This matters for several reasons.
Overlapping symptoms
Co-infections produce symptoms that overlap with Lyme disease: fatigue, cognitive impairment, joint pain, neurological symptoms. Without specific testing, it is impossible to know which pathogen is driving which symptom.
Immune suppression
Some co-infections (particularly Babesia and Bartonella) actively suppress immune function, making it harder for your body to fight Borrelia. This creates a compounding effect where multiple infections reinforce each other.
Treatment resistance
Different pathogens require different treatments. Antibiotics effective against Borrelia may have no effect on Babesia (a parasite, not a bacterium) or may be insufficient for Bartonella, which requires different antimicrobial agents.
Diagnostic gaps
Standard Lyme testing does not test for co-infections. If your physician only tests for Borrelia and treats accordingly, co-infections may persist untreated—explaining why symptoms continue despite antibiotic therapy.
The major co-infections
Babesia
Babesia microti, Babesia duncani, and related species
Babesia is a parasitic infection of the red blood cells—not a bacterium. This distinction is critical because antibiotics that treat bacterial infections are ineffective against parasites. Babesia is sometimes called the "malaria of the north" because it causes a similar pattern of red blood cell destruction.
Key symptoms
- Drenching night sweats—often the most distinctive symptom
- Cyclical fevers and chills
- Air hunger (feeling unable to take a deep breath)
- Severe fatigue disproportionate to activity level
- Headaches, particularly pressure-type headaches
- Dark urine (in severe cases, from red blood cell breakdown)
Why it matters for Lyme patients
Babesia co-infection is found in an estimated 20–40% of Lyme patients in endemic areas. It suppresses natural killer (NK) cell function, weakening the immune response against Borrelia. Patients with concurrent Babesia and Borrelia infections tend to have more severe and prolonged illness than those with Borrelia alone.
Treatment considerations
Babesia requires anti-parasitic agents (typically atovaquone with azithromycin, or quinine with clindamycin), not the antibiotics used for Borrelia. If Babesia is present but untreated, Lyme treatment alone is unlikely to resolve symptoms.
Bartonella
Bartonella henselae, Bartonella quintana, and related species
Bartonella is an intracellular bacterium with a particular affinity for the vascular endothelium (blood vessel lining) and red blood cells. It is increasingly recognized as a significant co-infection in Lyme patients, though its transmission by Ixodes ticks remains an area of active research.
Key symptoms
- Subcutaneous pain, particularly in the soles of the feet (a distinctive finding)
- Stretch mark-like lesions that appear without weight change (striae)
- Neuropsychiatric symptoms—anxiety, rage, depression, cognitive impairment
- Swollen lymph nodes
- Headaches, particularly behind the eyes
- Visual disturbances, eye pain
- Skin lesions or rashes that do not fit typical Lyme patterns
Why it matters for Lyme patients
Bartonella can be particularly challenging because it causes neuropsychiatric symptoms that may be attributed to "psychological" causes rather than infection. Patients with undiagnosed Bartonella co-infection may experience anxiety, irritability, and cognitive symptoms that do not improve with Lyme treatment alone. Bartonella is also notoriously difficult to culture and can persist in biofilm communities.
Treatment considerations
Bartonella typically requires a different antibiotic regimen than Borrelia, often involving a combination of agents over an extended period. Response to treatment can be slow, and Herxheimer reactions during Bartonella treatment can be particularly intense.
Ehrlichia and Anaplasma
Ehrlichia chaffeensis (Human Monocytic Ehrlichiosis) / Anaplasma phagocytophilum (Human Granulocytic Anaplasmosis)
Ehrlichia and Anaplasma are related intracellular bacteria that infect different types of white blood cells. Ehrlichia targets monocytes, while Anaplasma targets granulocytes (neutrophils). Both cause acute febrile illness that can become severe if untreated.
Key symptoms
- High fever with sudden onset
- Severe headache and muscle pain
- Low white blood cell count (leukopenia)
- Low platelet count (thrombocytopenia)
- Elevated liver enzymes
- Nausea, vomiting, and general malaise
Why they matter for Lyme patients
Ehrlichia and Anaplasma directly attack white blood cells—the very cells your immune system needs to fight Borrelia. Co-infection with either organism can significantly suppress immune function, creating a permissive environment for Borrelia to persist. Blood count abnormalities (low white cells, low platelets) in a Lyme patient should raise suspicion for these co-infections.
Treatment considerations
Both respond well to doxycycline, which is also used for Lyme disease. This is one case where the standard Lyme antibiotic may treat the co-infection simultaneously. However, proper diagnosis is still important for monitoring treatment response and identifying the full clinical picture.
Mycoplasma
Mycoplasma pneumoniae, Mycoplasma fermentans, and related species
Mycoplasma are among the smallest self-replicating organisms and lack a cell wall—which makes them inherently resistant to antibiotics that target cell wall synthesis (penicillins and cephalosporins). While Mycoplasma is commonly associated with respiratory infections, certain species are increasingly recognized as co-infections in chronic Lyme patients.
Key symptoms
- Chronic fatigue that persists despite rest
- Respiratory symptoms—persistent cough, shortness of breath
- Joint and muscle pain
- Cognitive impairment (brain fog)
- Skin rashes
- Symptoms that fluctuate and mimic autoimmune conditions
Why it matters for Lyme patients
Mycoplasma can trigger autoimmune-like responses and chronic inflammation. In patients with concurrent Lyme and Mycoplasma infections, the inflammatory burden is significantly increased, leading to more severe and persistent symptoms. Because Mycoplasma lacks a cell wall, common Lyme antibiotics like amoxicillin and ceftriaxone are ineffective against it.
Treatment considerations
Mycoplasma requires antibiotics that target protein synthesis (macrolides, tetracyclines, or fluoroquinolones) rather than cell wall synthesis. Treatment is often prolonged, and relapses can occur.
Testing for co-infections
Standard Lyme testing through most hospital laboratories does not include co-infection panels. If your physician has only tested for Borrelia, your co-infections may be entirely undiagnosed.
Why standard testing misses co-infections
- Standard Lyme panels (ELISA and Western blot) test only for Borrelia antibodies
- Co-infection testing must be ordered separately and specifically
- Many general practitioners are not trained to suspect or order co-infection testing
- Some co-infections (particularly Bartonella) are difficult to detect with standard serological methods
- Sensitivity of commercial tests varies significantly—negative results do not always mean absence of infection
Specialized co-infection testing
Standard hospital labs rarely test for co-infections unless specifically requested. We recommend ArminLabs (Augsburg, Germany) for co-infection diagnostics because their panels go significantly beyond what standard serology offers:
- TickPlex Plus — a single ELISA-based panel screening simultaneously for Babesia, Bartonella, Ehrlichia, Anaplasma, Mycoplasma, Rickettsia, EBV, Coxsackievirus, and Parvovirus B19 alongside Borrelia (including persister-form antigens). One blood draw, 10+ pathogens. Approximately 95% sensitivity and 98% specificity.
- EliSpot for co-infections — cellular immune testing (20–200x more sensitive than standard ELISA) for Bartonella, Babesia, Ehrlichia, Anaplasma, Chlamydia, Mycoplasma, and Rickettsia. Detects active immune responses even when antibody levels are undetectable.
- iSpot dual-cytokine assay — distinguishes active co-infection (IFN-γ dominant) from past resolved infection (IL-2 dominant), preventing unnecessary treatment for organisms your immune system has already cleared.
- ToxiPlex — screens for 5 mycotoxin classes (Aflatoxin B1, Deoxynivalenol, Fumonisin, Ochratoxin A, Zearalenone) that may be compounding immune suppression in treatment-resistant patients.
At Klinik St. Georg, comprehensive co-infection testing is a standard part of the initial diagnostic workup. The treatment team considers co-infections an essential factor in designing an effective treatment protocol—treating Borrelia alone without addressing co-infections is, in their clinical experience, one of the most common reasons patients fail to improve.
How co-infections change the treatment approach
Identifying co-infections does not just add diagnoses to your chart. It fundamentally changes the treatment strategy.
| Co-infection | Treatment requirement | Impact on Lyme treatment |
|---|---|---|
| Babesia | Anti-parasitic agents (not antibiotics) | Must be treated before or alongside Lyme treatment. Immune suppression from Babesia undermines Borrelia treatment. |
| Bartonella | Specific antibiotic combinations, often prolonged | Neuropsychiatric symptoms may not resolve with Lyme treatment alone. Separate antimicrobial strategy needed. |
| Ehrlichia / Anaplasma | Doxycycline (overlaps with Lyme treatment) | May respond to standard Lyme antibiotics, but monitoring of blood counts is essential. |
| Mycoplasma | Protein synthesis inhibitors (macrolides, tetracyclines) | Cell wall-targeting antibiotics (amoxicillin, ceftriaxone) are ineffective. Treatment strategy must account for Mycoplasma separately. |
What to do if you suspect co-infections
If you have been treated for Lyme disease but have not improved, or if your symptoms include patterns described above (night sweats, air hunger, neuropsychiatric symptoms, foot pain, blood count abnormalities), co-infections should be investigated.
- Ask your physician about co-infection testing—specifically request panels for Babesia, Bartonella, Ehrlichia, Anaplasma, and Mycoplasma
- Consider specialized laboratory testing—standard hospital labs may not offer comprehensive co-infection panels
- Seek a physician experienced in tick-borne disease—co-infection management requires clinical experience with these specific organisms
- Do not assume a negative test means no infection—sensitivity varies by test method and laboratory; clinical assessment matters alongside laboratory results
- Document your symptoms in detail—pattern recognition (cyclical fevers, night sweats, specific pain patterns) can guide diagnostic testing